Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026 at 09:58 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

2149611199 1 1 Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

The Company’s Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia–(April 20, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug … Continue reading

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	272.27	+0.00 (0.00%)
AAPL	304.91	+0.00 (0.00%)
AMD	474.32	+0.00 (0.00%)
BAC	64.00	+0.00 (0.00%)
GOOG	343.00	+0.00 (0.00%)
META	599.12	+0.00 (0.00%)
MSFT	503.81	+0.00 (0.00%)
NVDA	217.50	+0.00 (0.00%)
ORCL	145.48	+0.00 (0.00%)
TSLA	332.81	+0.00 (0.00%)

Symbol

Price

Change (%)

AMZN

272.27

+0.00 (0.00%)

AAPL

304.91

+0.00 (0.00%)

AMD

474.32

+0.00 (0.00%)

BAC

64.00

+0.00 (0.00%)

GOOG

343.00

+0.00 (0.00%)

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

More News

Recent Quotes